Black Diamond Reports Positive Silevertinib Phase 2 Data and FDA Feedback
Black Diamond Therapeutics reported updated Phase 2 data showing robust CNS activity for silevertinib and announced positive FDA feedback supporting a path to accelerated approval for NSCLC patients with untreated brain metastases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed